Management Team

James Garner

Dr James Garner 

Chief Executive Officer & Executive Director

Dr Garner is an experienced life sciences executive who has previously worked with companies ranging from small biotechs to multinational pharmaceutical companies such as Biogen and Takeda. His career has focused on regional and global development of new medicines from preclinical to commercialisation.

Dr Garner is a physician by training and holds an MBA from the University of Queensland. He began his career in hospital medicine and worked for a number of years as a corporate strategy consultant with Bain & Company before entering the pharmaceutical industry. Prior to joining Kazia Therapeutics in 2016, he led R&D strategy for Sanofi in Asia-Pacific and was based in Singapore.  Dr Garner is a member of the Australian Institute of Company Directors.

Read more

Dr John Friend 

Chief Medical Officer

Dr John Friend is a highly experienced oncology and haematology drug developer, driven by a passion for improving the lives of cancer patients. In a career spanning more than 25 years, Dr Friend has worked across a wide range of therapeutic areas in roles from early clinical research through to medical affairs. He was formerly the Senior Vice President of Medical and Scientific Affairs for the US business unit of Helsinn Therapeutics and most recently the Chief Medical Officer at Cellectar Biosciences, a clinical-stage, oncology-focused biotech company in the US.

Dr Friend gained his medical degree at Rutgers University (UMDNJ-Robert Wood Johnson) and he also holds a BA in chemistry from Southern Methodist University.

Read more

Karen Krumeich 

Chief Financial Officer

Ms Karen Krumeich has more than thirty years of experience in corporate finance, focused almost entirely on the life sciences sector. She has been responsible for driving the growth of numerous private and public biotech companies. For most of the last twenty years, Ms Krumeich served as Chief Financial Officer to growth-stage biotech companies, both public and private, including Soligenix, Inc, and Theravectys, Inc.

In addition to her accounting qualifications, Ms Krumeich is a qualified pharmacist.

Read more
Kate Hill

Kate Hill 

Company Secretary

Ms Kate Hill has over 20 years’ experience as an audit partner with Deloitte Touche Tohmatsu, working with ASX listed and privately owned clients. She has worked extensively in regulated environments including assisting with Initial Public Offerings, capital raising and general compliance, as well as operating in an audit environment.

In addition to her role at Kazia, Kate is a Non-Executive Director and Chair of the Audit Committee of CountPlus Limited (ASX:CUP) and Elmo Software Limited (ASX:ELO).  She is independent Chair of Seeing Machines Limited (AIM:SEE), as well as being a member of other Committees of those boards.

Ms Hill is a member of the Institute of Chartered Accountants in Australia and New Zealand, and a graduate of the Australian Institute of Company Directors.

Read more